Ontrak CEO resigns amid trade scandal

Published Date: 08 Mar 2023

Ontrak CEO Terren Peizer resigned on March 2, a day after US authorities charged him with insider trading, the company said.

Read Full News

Todays Updates


Early PET May Help Tailor Therapy in Hodgkin Lymphoma


A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection


Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC


Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers


The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term


A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer


Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Todays Updates


Early PET May Help Tailor Therapy in Hodgkin Lymphoma


A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection


Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC


Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers


The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term


A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer


Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survivors of childhood brain cancer are more likely to be held back in school

2.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

3.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

4.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

5.

Hypnotherapy may offer real benefits for cancer patient care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot